David Cipolla Selected Research

Ciprofloxacin (Cipro)

10/2020	Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies.
1/2019	Solid State Characterization of Ciprofloxacin Liposome Nanocrystals.
10/2018	Effective Treatment of Mycobacterium avium subsp. hominissuis and Mycobacterium abscessus Species Infections in Macrophages, Biofilm, and Mice by Using Liposomal Ciprofloxacin.
2/2018	Sweetening Inhaled Antibiotic Treatment for Eradication of Chronic Respiratory Biofilm Infection.
3/2016	Development of Liposomal Ciprofloxacin to Treat Lung Infections.
9/2013	Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.
8/2013	Liposomal formulations for inhalation.
12/2012	Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David Cipolla Research Topics

Disease

7	Infections 01/2021 - 08/2013
5	Cystic Fibrosis (Mucoviscidosis) 01/2022 - 09/2013
3	Pulmonary Arterial Hypertension 02/2022 - 01/2021
2	Asthma (Bronchial Asthma) 01/2022 - 01/2020
2	Respiratory Tract Infections (Respiratory Tract Infection) 01/2022 - 12/2012
2	Bronchiectasis 10/2020 - 09/2013
2	Neoplasms (Cancer) 01/2020 - 11/2010
2	Lung Diseases (Lung Disease) 02/2018 - 11/2010
1	Vascular Remodeling 02/2022
1	Hypoxia (Hypoxemia) 02/2022
1	Respiratory Tract Diseases (Respiratory Tract Disease) 01/2022
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2022
1	Cough 01/2021
1	COVID-19 01/2020
1	Dehydration (Water Stress) 01/2019
1	Tuberculosis (Tuberculoses) 03/2016
1	Tularemia 03/2016
1	Plague (Bubonic Plague) 03/2016
1	Mycoses (Diseases, Fungus) 03/2016
1	Q Fever (Fever, Q) 03/2016
1	Heart Diseases (Heart Disease) 11/2010
1	Emphysema 11/2010
1	Thymoma (Thymic Carcinoma) 02/2004

Drug/Important Bio-Agent (IBA)

8	Ciprofloxacin (Cipro)FDA LinkGeneric 10/2020 - 12/2012
6	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 09/2013
3	treprostinil FDA Link 02/2022 - 01/2021
3	AerosolsIBA 01/2022 - 11/2010
2	SuspensionsIBA 02/2022 - 01/2021
2	Mannitol (Osmitrol)FDA LinkGeneric 01/2022 - 02/2018
2	Pharmaceutical PreparationsIBA 01/2022 - 01/2020
1	Semaxinib (SU5416)IBA 02/2022
1	Muscarinic AgonistsIBA 01/2022
1	Antiviral Agents (Antivirals)IBA 01/2022
1	Cholinergic ReceptorsIBA 01/2022
1	Surface-Active Agents (Surfactants)IBA 01/2022
1	Prostaglandins IIBA 01/2022
1	Vancomycin FDA LinkGeneric 01/2021
1	PowdersIBA 01/2021
1	Bradykinin B2 Receptor AntagonistsIBA 01/2021
1	ProdrugsIBA 01/2021
1	ProstaglandinsIBA 01/2021
1	Epoprostenol (Prostacyclin)FDA LinkGeneric 01/2021
1	Cyclooxygenase InhibitorsIBA 01/2021
1	LipoglycopeptidesIBA 01/2021
1	TachykininsIBA 01/2021
1	Vasodilator Agents (Vasodilators)IBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	Liposomes (Liposome)IBA 01/2020
1	Biological Warfare AgentsIBA 03/2016
1	Tobramycin (Nebcin)FDA LinkGeneric 09/2013
1	Aztreonam FDA LinkGeneric 09/2013
1	Amikacin (A.M.K)FDA LinkGeneric 08/2013

Therapy/Procedure

2	Therapeutics 02/2018 - 02/2004
1	Tobacco Use Cessation Devices 11/2010
1	Nebulizers and Vaporizers (Inhaler) 11/2010